{"result": "(\"entity\"<|>NÁUSEAS Y VÓMITOS<|>EVENT<|>Náuseas y vómitos are common symptoms experienced by cancer patients, often requiring dietary adjustments to manage them effectively.)\n##\n(\"entity\"<|>HIPOGEUSIA<|>EVENT<|>Hipogeusia refers to a reduced ability to taste, which can affect the dietary choices and nutritional intake of cancer patients.)\n##\n(\"entity\"<|>DISGEUSIA<|>EVENT<|>Disgeusia is a condition characterized by altered taste perception, impacting the appetite and food preferences of cancer patients.)\n##\n(\"entity\"<|>XEROSTOMÍA<|>EVENT<|>Xerostomía, or dry mouth, is a condition that can affect cancer patients, influencing their ability to eat and enjoy food.)\n##\n(\"entity\"<|>ESOFAGITIS<|>EVENT<|>Esofagitis is inflammation of the esophagus that can occur in cancer patients, often requiring dietary modifications for comfort.)\n##\n(\"entity\"<|>SACIEDAD PRECOZ<|>EVENT<|>Saciedad precoz refers to early satiety, a condition where patients feel full after consuming only a small amount of food, affecting their nutritional intake.)\n##\n(\"entity\"<|>ESTREÑIMIENTO<|>EVENT<|>Estreñimiento, or constipation, is a common issue faced by cancer patients, often requiring dietary interventions to alleviate symptoms.)\n##\n(\"entity\"<|>NEUTROPENIA<|>EVENT<|>Neutropenia is a condition characterized by low levels of neutrophils, which can affect dietary choices and food safety for cancer patients.)\n##\n(\"relationship\"<|>NÁUSEAS Y VÓMITOS<|>NUTRICIÓN EN ONCOLOGÍA<|>Náuseas y vómitos are symptoms that require specific dietary strategies as part of nutrition in oncology to improve patient comfort and intake.<|>8)\n##\n(\"relationship\"<|>HIPOGEUSIA<|>NUTRICIÓN EN ONCOLOGÍA<|>Hipogeusia impacts the dietary choices of cancer patients, necessitating tailored nutritional strategies in oncology.<|>7)\n##\n(\"relationship\"<|>DISGEUSIA<|>NUTRICIÓN EN ONCOLOGÍA<|>Disgeusia affects the appetite and food preferences of cancer patients, requiring adjustments in their nutritional management.<|>7)\n##\n(\"relationship\"<|>XEROSTOMÍA<|>NUTRICIÓN EN ONCOLOGÍA<|>Xerostomía can significantly impact the ability of cancer patients to eat, necessitating specific dietary recommendations in oncology.<|>7)\n##\n(\"relationship\"<|>ESOFAGITIS<|>NUTRICIÓN EN ONCOLOGÍA<|>Esofagitis can lead to difficulties in eating, requiring dietary modifications as part of nutritional care in oncology.<|>7)\n##\n(\"relationship\"<|>SACIEDAD PRECOZ<|>NUTRICIÓN EN ONCOLOGÍA<|>Saciedad precoz affects food intake in cancer patients, necessitating dietary strategies to ensure adequate nutrition.<|>7)\n##\n(\"relationship\"<|>ESTREÑIMIENTO<|>NUTRICIÓN EN ONCOLOGÍA<|>Estreñimiento is a common issue in cancer patients that requires dietary interventions to improve bowel health and overall nutrition.<|>7)\n##\n(\"relationship\"<|>NEUTROPENIA<|>NUTRICIÓN EN ONCOLOGÍA<|>Neutropenia affects food safety and dietary choices for cancer patients, requiring careful nutritional management.<|>7)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: cológicos es la anorexia, que puede hacer fracasar el soporte nutricional oral, porque el paciente es incapaz de cubrir sus necesidades energéticas. Para combatirla, disponemos de distintos tratamientos farmacológicos:\n\n- El acetato de megestrol (AM) en dosis de 160 a 1600 mg/día, mejora el apetito y logra aumento de peso en pacientes con cáncer, aunque no ha demostrado un aumento de la masa magra, ni de la supervivencia. La duración recomendada del tratamiento es de 6 semanas o más. El acetato de megestrol está considerado como un fármaco relativamente no tóxico, con baja incidencia de efectos adversos. La dosis más habitual es de 320-480 mg/día. En dosis > 800 mg/día podría existir un aumento del riesgo de trombosis venosa, por lo que hay que tener precaución en pacientes con factores predisponentes. Tras tratamientos prolongados se puede producir insuficiencia suprarrenal.\n\n- Ciproheptadina: es un potente antagonista de la histamina y la serotonina. Se ha encontrado que aumenta el apetito en pacientes con cáncer avanzado, aunque sin resultado positivo sobre el peso, salvo en aquellos con síndrome carcinoide. Un efecto adverso de su uso es la sedación, lo que limita su utilización en pacientes con cáncer avanzado por el riesgo de empeoramiento cognitivo. Actualmente no se recomienda su uso generalizado como estimulante del apetito.\n\n- Mirtazapina: es un antidepresivo tetracíclico que aumenta la liberación de noradrenalina y serotonina y también es antagonista de los receptores serotoninérgicos. A dosis de 15 a 30 mg/día, ha demostrado mejoría del apetito y de la calidad de vida en pacientes con cáncer. Pese a que puede ser eficaz en la caquexia relacionada con el cáncer, se necesitan estudios antes de poder recomendar su uso en las guías de práctica clínica.\n\n## Tabla 3. Consejos dietéticos durante el tratamiento antineoplásico.\n\n| Problemas | Dieta | Alimentos a evitar |\n|-----------|-------|-------------------|\n| Náuseas y vómitos | Líquidos claros, no grasos y no ácidos | Lácteos, sopas de cremas, fritos, postres dulces |\n| Hipogeusia | Dieta habitual con alimentos muy condimentados | Alimentos blandos, carnes simples, alimentos sin sal |\n| Disgeusia | Dieta habitual con muchos alimentos fríos, productos lácteos. Animarlos a probar nuevos alimentos | Carnes rojas, chocolate, café, té |\n| Xerostomía | Alimentos que estimulan la salivación, ácidos o muy dulces. Alimentos húmedos (salsas, sopas, cereales con leche, etc.) | Alimentos secos como pan, galletas, plátanos. Alimentos muy calientes. Alimentos grasos |\n| Esofagitis | Dieta líquida y blanda | Cítricos, alimentos crujientes o crudos, alimentos muy fríos o muy calientes |\n| Saciedad precoz | Comidas pequeñas y frecuentes, introduciendo alimentos de alta densidad calórica | Comidas muy grasas |\n| Estreñimiento | Dieta habitual con fibra añadida Aumentar la ingesta hídrica | - |\n| Neutropenia | Dieta con alimentos bien cocinados | Alimentos crudos, quesos o miel sin pasteurizar, condimentos secos añadidos tras la cocción, suplementos de herbolario |\n---\n644     BLOQUE: NUTRICIÓN EN ONCOLOGÍA\n\n- Corticoides: los más empleados son dexametasona, prednisolona y metil-prednisolona. Han demostrado mejorar el apetito, disminuir las náuseas y mejorar la calidad de vida, aunque no mejorar el peso. Su mecanismo de acción está probablemente relacionado con sus propiedades antiinflamatorias y euforizantes. El efecto antianorético de los corticosteroides es transitorio y desaparece tras unas semanas, cuando la miopatía y la inmunosupresión se hacen evidentes. Además, también producen insulinorresistencia a corto plazo y osteopenia a largo plazo22. Debido a sus efectos adversos se recomienda únicamente para ciclos cortos de tratamiento, o en pacientes con una corta esperanza de vida especialmente si tienen otros síntomas, como dolor o náuseas que puedan mejorar con este tratamiento. En ciclos más prolongados de tratamiento, es preferible el acetato de megestrol.\n\n- Anabolizantes: debido a que en el cáncer existe un descenso de la masa muscular, los derivados de la testosterona se han considerado como una posible opción terapéutica. Aunque han demostrado efectos positivos en algunos ensayos clínicos, son menos efectivos que el acetato de\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>ACETATO DE MEGESTROL<|>ORGANIZATION<|>Acetato de megestrol is a medication used to improve appetite and increase weight in cancer patients, though it does not increase lean mass or survival rates.)\n##\n(\"entity\"<|>CIPROHEPTADINA<|>ORGANIZATION<|>Ciproheptadina is a potent antagonist of histamine and serotonin, found to increase appetite in advanced cancer patients but with limited effectiveness on weight.)\n##\n(\"entity\"<|>MIRTAPAZAPINA<|>ORGANIZATION<|>Mirtazapina is a tetracyclic antidepressant that increases the release of norepinephrine and serotonin, showing improvement in appetite and quality of life in cancer patients.)\n##\n(\"entity\"<|>CORTICOIDES<|>ORGANIZATION<|>Corticosteroids like dexamethasone, prednisolone, and methylprednisolone are used to improve appetite and reduce nausea in cancer patients, though they have various side effects.)\n##\n(\"entity\"<|>ANABOLIZANTES<|>ORGANIZATION<|>Anabolics are testosterone derivatives considered for therapeutic use in cancer patients to counteract muscle mass loss, though they are less effective than acetato de megestrol.)\n##\n(\"entity\"<|>NUTRICIÓN EN ONCOLOGÍA<|>EVENT<|>Nutrition in oncology refers to dietary strategies and interventions aimed at improving the nutritional status and quality of life of cancer patients.)\n##\n(\"relationship\"<|>ACETATO DE MEGESTROL<|>CORTICOIDES<|>Both acetato de megestrol and corticosteroids are used to manage appetite and quality of life in cancer patients, but they have different mechanisms and side effects.<|>7)\n##\n(\"relationship\"<|>CIPROHEPTADINA<|>MIRTAPAZAPINA<|>Ciproheptadina and mirtazapina are both medications aimed at improving appetite in cancer patients, though they have different effects and side effects.<|>6)\n##\n(\"relationship\"<|>MIRTAPAZAPINA<|>CORTICOIDES<|>Mirtazapina and corticosteroids are both used to enhance the quality of life and manage symptoms in cancer patients, focusing on appetite and nausea.<|>6)\n##\n(\"relationship\"<|>ANABOLIZANTES<|>ACETATO DE MEGESTROL<|>Anabolics and acetato de megestrol are both considered for therapeutic use in cancer patients to address muscle mass loss and appetite issues.<|>5)\n##\n(\"relationship\"<|>NUTRICIÓN EN ONCOLOGÍA<|>ACETATO DE MEGESTROL<|>Nutrition in oncology includes the use of acetato de megestrol as part of dietary strategies to improve the nutritional status of cancer patients.<|>8)\n##\n(\"relationship\"<|>NUTRICIÓN EN ONCOLOGÍA<|>CORTICOIDES<|>Nutrition in oncology involves the use of corticosteroids to manage symptoms like appetite loss and nausea in cancer patients.<|>8)\n<|COMPLETE|>"}]}